Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study.

Journal of lipids

Santos-Ferreira C, Baptista R, Oliveira-Santos M, Costa R, Pereira Moura J, Gonçalves L.
PMID: 31485353
J Lipids. 2019 Aug 07;2019:1698610. doi: 10.1155/2019/1698610. eCollection 2019.

BACKGROUND: The apolipoprotein E (APOE) polymorphisms are associated with cardiovascular (CV) disease, but its interaction with type 2 diabetes mellitus (T2DM) long-term incidence is unknown. We investigated the association between APOE genotype and long-term (i) CV events and (ii)...

Cite
Santos-Ferreira C, Baptista R, Oliveira-Santos M, et al. Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study. J Lipids. 2019;2019:1698610doi: 10.1155/2019/1698610.
Santos-Ferreira, C., Baptista, R., Oliveira-Santos, M., Costa, R., Pereira Moura, J., & Gonçalves, L. (2019). Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study. Journal of lipids, 20191698610. https://doi.org/10.1155/2019/1698610
Santos-Ferreira, Cátia, et al. "Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study." Journal of lipids vol. 2019 (2019): 1698610. doi: https://doi.org/10.1155/2019/1698610
Santos-Ferreira C, Baptista R, Oliveira-Santos M, Costa R, Pereira Moura J, Gonçalves L. Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study. J Lipids. 2019 Aug 07;2019:1698610. doi: 10.1155/2019/1698610. eCollection 2019. PMID: 31485353; PMCID: PMC6702854.
Copy Download .nbib Format: NLM
Association of Apolipoprotein e2 Allele with Insulin Resistance and Risk of Type 2 Diabetes Mellitus Among an Admixed Population of Mexico.

Diabetes, metabolic syndrome and obesity : targets and therapy

Gonzalez-Aldaco K, Roman S, Torres-Reyes LA, Panduro A.
PMID: 33116704
Diabetes Metab Syndr Obes. 2020 Oct 06;13:3527-3534. doi: 10.2147/DMSO.S268329. eCollection 2020.

RESULTS: The rate of dyslipidemias and IR increased by BMI category among the control subjects. The greater shift in the prevalence of dyslipidemia was observed from normal weight (51.4%) to overweight (76.6%), p

Cite
Gonzalez-Aldaco K, Roman S, Torres-Reyes LA, et al. Association of Apolipoprotein e2 Allele with Insulin Resistance and Risk of Type 2 Diabetes Mellitus Among an Admixed Population of Mexico. Diabetes Metab Syndr Obes. 2020;13:3527-3534doi: 10.2147/DMSO.S268329.
Gonzalez-Aldaco, K., Roman, S., Torres-Reyes, L. A., & Panduro, A. (2020). Association of Apolipoprotein e2 Allele with Insulin Resistance and Risk of Type 2 Diabetes Mellitus Among an Admixed Population of Mexico. Diabetes, metabolic syndrome and obesity : targets and therapy, 133527-3534. https://doi.org/10.2147/DMSO.S268329
Gonzalez-Aldaco, Karina, et al. "Association of Apolipoprotein e2 Allele with Insulin Resistance and Risk of Type 2 Diabetes Mellitus Among an Admixed Population of Mexico." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 13 (2020): 3527-3534. doi: https://doi.org/10.2147/DMSO.S268329
Gonzalez-Aldaco K, Roman S, Torres-Reyes LA, Panduro A. Association of Apolipoprotein e2 Allele with Insulin Resistance and Risk of Type 2 Diabetes Mellitus Among an Admixed Population of Mexico. Diabetes Metab Syndr Obes. 2020 Oct 06;13:3527-3534. doi: 10.2147/DMSO.S268329. eCollection 2020. PMID: 33116704; PMCID: PMC7547770.
Copy Download .nbib Format: NLM
Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2.

Case reports in nephrology and dialysis

Fukunaga M, Nagahama K, Aoki M, Shimizu A, Hara S, Matsunaga A, Muso E, Saito T.
PMID: 29692990
Case Rep Nephrol Dial. 2018 Mar 20;8(1):45-55. doi: 10.1159/000487919. eCollection 2018.

A 20-year-old female student underwent renal biopsy because of chance proteinuria and hematuria. Histological study revealed a membranous nephropathy-like appearance by light microscopy. But immunoglobulins and complements were negative in the glomerulus by immunofluorescence study. On the other hand,...

Cite
Fukunaga M, Nagahama K, Aoki M, et al. Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2. Case Rep Nephrol Dial. 2018;8(1):45-55doi: 10.1159/000487919.
Fukunaga, M., Nagahama, K., Aoki, M., Shimizu, A., Hara, S., Matsunaga, A., Muso, E., & Saito, T. (2018). Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2. Case reports in nephrology and dialysis, 8(1), 45-55. https://doi.org/10.1159/000487919
Fukunaga, Megumu, et al. "Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2." Case reports in nephrology and dialysis vol. 8,1 (2018): 45-55. doi: https://doi.org/10.1159/000487919
Fukunaga M, Nagahama K, Aoki M, Shimizu A, Hara S, Matsunaga A, Muso E, Saito T. Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2. Case Rep Nephrol Dial. 2018 Mar 20;8(1):45-55. doi: 10.1159/000487919. eCollection 2018. PMID: 29692990; PMCID: PMC5903162.
Copy Download .nbib Format: NLM
Posttransplant proteinuria due to Apolipoprotein E2 deposition in a kidney allograft.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Ramakrishnan M, Fields T, Zhang D, Owoyemi IO, Gupta A, Klein JA, Herrera NS, Gupta M, Cibrik DM.
PMID: 34327815
Am J Transplant. 2021 Dec;21(12):4068-4072. doi: 10.1111/ajt.16774. Epub 2021 Aug 16.

Lipoprotein deposition disorders limited to the kidney and causing proteinuria are rare. We present a case of nephrotic range proteinuria presenting within 4 months after deceased donor renal transplantation in a patient with end-stage kidney disease presumed secondary to...

Cite
Ramakrishnan M, Fields T, Zhang D, et al. Posttransplant proteinuria due to Apolipoprotein E2 deposition in a kidney allograft. Am J Transplant. 2021;21(12):4068-4072doi: 10.1111/ajt.16774.
Ramakrishnan, M., Fields, T., Zhang, D., Owoyemi, I. O., Gupta, A., Klein, J. A., Herrera, N. S., Gupta, M., & Cibrik, D. M. (2021). Posttransplant proteinuria due to Apolipoprotein E2 deposition in a kidney allograft. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 21(12), 4068-4072. https://doi.org/10.1111/ajt.16774
Ramakrishnan, Madhuri, et al. "Posttransplant proteinuria due to Apolipoprotein E2 deposition in a kidney allograft." American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons vol. 21,12 (2021): 4068-4072. doi: https://doi.org/10.1111/ajt.16774
Ramakrishnan M, Fields T, Zhang D, Owoyemi IO, Gupta A, Klein JA, Herrera NS, Gupta M, Cibrik DM. Posttransplant proteinuria due to Apolipoprotein E2 deposition in a kidney allograft. Am J Transplant. 2021 Dec;21(12):4068-4072. doi: 10.1111/ajt.16774. Epub 2021 Aug 16. PMID: 34327815.
Copy Download .nbib Format: NLM
Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases.

Current neurovascular research

Ceci FM, Ceccanti M, Petrella C, Vitali M, Messina MP, Chaldakov GN, Greco A, Ralli M, Lucarelli M, Angeloni A, Fiore M, Ferraguti G.
PMID: 33823779
Curr Neurovasc Res. 2021;18(1):150-161. doi: 10.2174/1567202618666210406123503.

Lipoprotein disorders are a major risk factor for atherosclerotic neuro-cardiovascular disease (ACVD) and are heavily influenced by lifestyle, including alcohol drinking. Moderate drinkers have a lower ACVD risk than abstainers due to their higher levels of high-density lipoprotein (HDL)...

Cite
Ceci FM, Ceccanti M, Petrella C, et al. Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases. Curr Neurovasc Res. 2021;18(1):150-161doi: 10.2174/1567202618666210406123503.
Ceci, F. M., Ceccanti, M., Petrella, C., Vitali, M., Messina, M. P., Chaldakov, G. N., Greco, A., Ralli, M., Lucarelli, M., Angeloni, A., Fiore, M., & Ferraguti, G. (2021). Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases. Current neurovascular research, 18(1), 150-161. https://doi.org/10.2174/1567202618666210406123503
Ceci, Flavio M, et al. "Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases." Current neurovascular research vol. 18,1 (2021): 150-161. doi: https://doi.org/10.2174/1567202618666210406123503
Ceci FM, Ceccanti M, Petrella C, Vitali M, Messina MP, Chaldakov GN, Greco A, Ralli M, Lucarelli M, Angeloni A, Fiore M, Ferraguti G. Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases. Curr Neurovasc Res. 2021;18(1):150-161. doi: 10.2174/1567202618666210406123503. PMID: 33823779.
Copy Download .nbib Format: NLM
Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm.

World journal of clinical cases

Kei A, Miltiadous G, Bairaktari E, Hadjivassiliou M, Cariolou M, Elisaf M.
PMID: 25879010
World J Clin Cases. 2015 Apr 16;3(4):371-6. doi: 10.12998/wjcc.v3.i4.371.

Dysbetalipoproteinemia is a rare familial dyslipidemia characterized by approximately equally elevated serum cholesterol and triglyceride levels due to accumulated remnant lipoproteins in apolipoprotein E2/E2 homozygotes. It is associated with an increased risk for premature cardiovascular disease. Thus, making a...

Cite
Kei A, Miltiadous G, Bairaktari E, et al. Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm. World J Clin Cases. 2015;3(4):371-6doi: 10.12998/wjcc.v3.i4.371.
Kei, A., Miltiadous, G., Bairaktari, E., Hadjivassiliou, M., Cariolou, M., & Elisaf, M. (2015). Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm. World journal of clinical cases, 3(4), 371-6. https://doi.org/10.12998/wjcc.v3.i4.371
Kei, Anastazia, et al. "Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm." World journal of clinical cases vol. 3,4 (2015): 371-6. doi: https://doi.org/10.12998/wjcc.v3.i4.371
Kei A, Miltiadous G, Bairaktari E, Hadjivassiliou M, Cariolou M, Elisaf M. Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm. World J Clin Cases. 2015 Apr 16;3(4):371-6. doi: 10.12998/wjcc.v3.i4.371. PMID: 25879010; PMCID: PMC4391008.
Copy Download .nbib Format: NLM
Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia.

JACC. Basic to translational science

Blanchard V, Croyal M, Khantalin I, Ramin-Mangata S, Chemello K, Nativel B, Blom DJ, Marais AD, Lambert G.
PMID: 31312765
JACC Basic Transl Sci. 2019 Jun 24;4(3):425-427. doi: 10.1016/j.jacbts.2019.03.002. eCollection 2019 Jun.

No abstract available.

Cite
Blanchard V, Croyal M, Khantalin I, et al. Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. JACC Basic Transl Sci. 2019;4(3):425-427doi: 10.1016/j.jacbts.2019.03.002.
Blanchard, V., Croyal, M., Khantalin, I., Ramin-Mangata, S., Chemello, K., Nativel, B., Blom, D. J., Marais, A. D., & Lambert, G. (2019). Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. JACC. Basic to translational science, 4(3), 425-427. https://doi.org/10.1016/j.jacbts.2019.03.002
Blanchard, Valentin, et al. "Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia." JACC. Basic to translational science vol. 4,3 (2019): 425-427. doi: https://doi.org/10.1016/j.jacbts.2019.03.002
Blanchard V, Croyal M, Khantalin I, Ramin-Mangata S, Chemello K, Nativel B, Blom DJ, Marais AD, Lambert G. Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia. JACC Basic Transl Sci. 2019 Jun 24;4(3):425-427. doi: 10.1016/j.jacbts.2019.03.002. eCollection 2019 Jun. PMID: 31312765; PMCID: PMC6610154.
Copy Download .nbib Format: NLM
Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature.

Case reports in nephrology and urology

Kawanishi K, Sawada A, Ochi A, Moriyama T, Mitobe M, Mochizuki T, Honda K, Oda H, Nishikawa T, Nitta K.
PMID: 24570682
Case Rep Nephrol Urol. 2013 Nov 28;3(2):128-35. doi: 10.1159/000356849. eCollection 2013 Jul.

Most cases of type III hyperlipoproteinemia are accounted for by apolipoprotein E2 (apoE2) homozygotes, a genetic mutation of apoE (Arg158Cys). Glomerulopathy with homozygous apoE2 is rare and characterized by marked foam cell infiltration in the glomerular capillaries and mesangium....

Cite
Kawanishi K, Sawada A, Ochi A, et al. Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature. Case Rep Nephrol Urol. 2013;3(2):128-35doi: 10.1159/000356849.
Kawanishi, K., Sawada, A., Ochi, A., Moriyama, T., Mitobe, M., Mochizuki, T., Honda, K., Oda, H., Nishikawa, T., & Nitta, K. (2013). Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature. Case reports in nephrology and urology, 3(2), 128-35. https://doi.org/10.1159/000356849
Kawanishi, Kunio, et al. "Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature." Case reports in nephrology and urology vol. 3,2 (2013): 128-35. doi: https://doi.org/10.1159/000356849
Kawanishi K, Sawada A, Ochi A, Moriyama T, Mitobe M, Mochizuki T, Honda K, Oda H, Nishikawa T, Nitta K. Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature. Case Rep Nephrol Urol. 2013 Nov 28;3(2):128-35. doi: 10.1159/000356849. eCollection 2013 Jul. PMID: 24570682; PMCID: PMC3924710.
Copy Download .nbib Format: NLM
A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka.

Clinical nephrology. Case studies

Hirashima H, Komiya T, Toriu N, Hara S, Matsunaga A, Saito T, Muso E.
PMID: 30542638
Clin Nephrol Case Stud. 2018 Nov 30;6:45-51. doi: 10.5414/CNCS109509. eCollection 2018.

A 79-year-old man was admitted to our hospital for proteinuria due to nephrotic syndrome. Renal biopsy revealed focal sclerosis and foam cell infiltration in the glomerulus. In addition, electron microscopic findings (EM) revealed peculiar electron-dense deposits (EDDs) in both...

Cite
Hirashima H, Komiya T, Toriu N, et al. A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka. Clin Nephrol Case Stud. 2018;6:45-51doi: 10.5414/CNCS109509.
Hirashima, H., Komiya, T., Toriu, N., Hara, S., Matsunaga, A., Saito, T., & Muso, E. (2018). A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka. Clinical nephrology. Case studies, 645-51. https://doi.org/10.5414/CNCS109509
Hirashima, Hisako, et al. "A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka." Clinical nephrology. Case studies vol. 6 (2018): 45-51. doi: https://doi.org/10.5414/CNCS109509
Hirashima H, Komiya T, Toriu N, Hara S, Matsunaga A, Saito T, Muso E. A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka. Clin Nephrol Case Stud. 2018 Nov 30;6:45-51. doi: 10.5414/CNCS109509. eCollection 2018. PMID: 30542638; PMCID: PMC6287602.
Copy Download .nbib Format: NLM
Prediction of dyslipidemia using gene mutations, family history of diseases and anthropometric indicators in children and adolescents: The CASPIAN-III study.

Computational and structural biotechnology journal

Marateb HR, Mohebian MR, Javanmard SH, Tavallaei AA, Tajadini MH, Heidari-Beni M, Mañanas MA, Motlagh ME, Heshmat R, Mansourian M, Kelishadi R.
PMID: 30026888
Comput Struct Biotechnol J. 2018 Mar 02;16:121-130. doi: 10.1016/j.csbj.2018.02.009. eCollection 2018.

Dyslipidemia, the disorder of lipoprotein metabolism resulting in high lipid profile, is an important modifiable risk factor for coronary heart diseases. It is associated with more than four million worldwide deaths per year. Half of the children with dyslipidemia...

Cite
Marateb HR, Mohebian MR, Javanmard SH, et al. Prediction of dyslipidemia using gene mutations, family history of diseases and anthropometric indicators in children and adolescents: The CASPIAN-III study. Comput Struct Biotechnol J. 2018;16:121-130doi: 10.1016/j.csbj.2018.02.009.
Marateb, H. R., Mohebian, M. R., Javanmard, S. H., Tavallaei, A. A., Tajadini, M. H., Heidari-Beni, M., Mañanas, M. A., Motlagh, M. E., Heshmat, R., Mansourian, M., & Kelishadi, R. (2018). Prediction of dyslipidemia using gene mutations, family history of diseases and anthropometric indicators in children and adolescents: The CASPIAN-III study. Computational and structural biotechnology journal, 16121-130. https://doi.org/10.1016/j.csbj.2018.02.009
Marateb, Hamid R, et al. "Prediction of dyslipidemia using gene mutations, family history of diseases and anthropometric indicators in children and adolescents: The CASPIAN-III study." Computational and structural biotechnology journal vol. 16 (2018): 121-130. doi: https://doi.org/10.1016/j.csbj.2018.02.009
Marateb HR, Mohebian MR, Javanmard SH, Tavallaei AA, Tajadini MH, Heidari-Beni M, Mañanas MA, Motlagh ME, Heshmat R, Mansourian M, Kelishadi R. Prediction of dyslipidemia using gene mutations, family history of diseases and anthropometric indicators in children and adolescents: The CASPIAN-III study. Comput Struct Biotechnol J. 2018 Mar 02;16:121-130. doi: 10.1016/j.csbj.2018.02.009. eCollection 2018. PMID: 30026888; PMCID: PMC6050175.
Copy Download .nbib Format: NLM
Apolipoprotein E2 Promotes the Migration and Invasion of Pancreatic Cancer Cells via Activation of the ERK1/2 Signaling Pathway.

Cancer management and research

Wang H, Du S, Cai J, Wang J, Shen X.
PMID: 33376407
Cancer Manag Res. 2020 Dec 22;12:13161-13171. doi: 10.2147/CMAR.S284115. eCollection 2020.

BACKGROUND: Apolipoprotein E2 (ApoE2) is reported to be essential for cell metastasis and proliferation and has been considered a potential diagnostic marker in many cancers. However, the function of ApoE2 in the metastasis of pancreatic cancer, as well as...

Cite
Wang H, Du S, Cai J, et al. Apolipoprotein E2 Promotes the Migration and Invasion of Pancreatic Cancer Cells via Activation of the ERK1/2 Signaling Pathway. Cancer Manag Res. 2020;12:13161-13171doi: 10.2147/CMAR.S284115.
Wang, H., Du, S., Cai, J., Wang, J., & Shen, X. (2020). Apolipoprotein E2 Promotes the Migration and Invasion of Pancreatic Cancer Cells via Activation of the ERK1/2 Signaling Pathway. Cancer management and research, 1213161-13171. https://doi.org/10.2147/CMAR.S284115
Wang, Hui, et al. "Apolipoprotein E2 Promotes the Migration and Invasion of Pancreatic Cancer Cells via Activation of the ERK1/2 Signaling Pathway." Cancer management and research vol. 12 (2020): 13161-13171. doi: https://doi.org/10.2147/CMAR.S284115
Wang H, Du S, Cai J, Wang J, Shen X. Apolipoprotein E2 Promotes the Migration and Invasion of Pancreatic Cancer Cells via Activation of the ERK1/2 Signaling Pathway. Cancer Manag Res. 2020 Dec 22;12:13161-13171. doi: 10.2147/CMAR.S284115. eCollection 2020. PMID: 33376407; PMCID: PMC7764636.
Copy Download .nbib Format: NLM
APOE2 promotes the development and progression of subretinal neovascularization in age-related macular degeneration via MAPKs signaling pathway.

Saudi journal of biological sciences

Sun Y, Song R, Ai Y, Zhu J, He J, Dang M, Li H.
PMID: 32994736
Saudi J Biol Sci. 2020 Oct;27(10):2770-2777. doi: 10.1016/j.sjbs.2020.06.037. Epub 2020 Jun 27.

BACKGROUND: Neovascular age-related macular degeneration (nvAMD) is one of the main pathological features of wet AMD. Apolipoprotein E2 is involved in the formation of nvAMD but the molecular mechanism has not been reported.METHODS: The APOE alleles in AMD patients...

Cite
Sun Y, Song R, Ai Y, et al. APOE2 promotes the development and progression of subretinal neovascularization in age-related macular degeneration via MAPKs signaling pathway. Saudi J Biol Sci. 2020;27(10):2770-2777doi: 10.1016/j.sjbs.2020.06.037.
Sun, Y., Song, R., Ai, Y., Zhu, J., He, J., Dang, M., & Li, H. (2020). APOE2 promotes the development and progression of subretinal neovascularization in age-related macular degeneration via MAPKs signaling pathway. Saudi journal of biological sciences, 27(10), 2770-2777. https://doi.org/10.1016/j.sjbs.2020.06.037
Sun, Yiwen, et al. "APOE2 promotes the development and progression of subretinal neovascularization in age-related macular degeneration via MAPKs signaling pathway." Saudi journal of biological sciences vol. 27,10 (2020): 2770-2777. doi: https://doi.org/10.1016/j.sjbs.2020.06.037
Sun Y, Song R, Ai Y, Zhu J, He J, Dang M, Li H. APOE2 promotes the development and progression of subretinal neovascularization in age-related macular degeneration via MAPKs signaling pathway. Saudi J Biol Sci. 2020 Oct;27(10):2770-2777. doi: 10.1016/j.sjbs.2020.06.037. Epub 2020 Jun 27. PMID: 32994736; PMCID: PMC7499293.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries